Related Experiment Videos
Update of pediatric liver transplantation
E M Alonso1, R Gonzalez-Vallina, P F Whitington
1University of Chicago, Department of Pediatrics, IL 60637-1470.
Insights
Pediatric liver transplantation offers a life-saving solution for children with end-stage liver disease, improving health outcomes and survival rates. Innovations like living donor transplants enhance organ availability and patient recovery.
Area of Science:
- Pediatric Hepatology
- Transplant Surgery
- Immunology
Background:
- Liver transplantation is a primary treatment for pediatric end-stage liver disease.
- Indications include hepatic insufficiency and metabolic liver diseases.
- Transplantation is considered when alternative therapies are unavailable.
Purpose of the Study:
- To review the indications, contraindications, and outcomes of pediatric liver transplantation.
- To highlight innovations in organ donation and immunosuppression protocols.
- To assess the impact of transplantation on children's long-term health and development.
Main Methods:
- Review of current literature and clinical practices in pediatric liver transplantation.
- Analysis of immunosuppression regimens and rejection management strategies.
- Evaluation of survival rates and post-transplant outcomes in pediatric patients.
Main Results:
- Living related liver transplantation has increased organ supply and reduced mortality for infants.
- Standard immunosuppression involves methylprednisolone, azathioprine, and cyclosporine.
- Acute rejection is effectively managed with corticosteroids and OKT3, with a 90% control rate.
- Survival rates range from 70%-90%, with significant improvements in nutritional status, motor development, and overall health.
Conclusions:
- Pediatric liver transplantation is a highly effective therapy with improving outcomes.
- Innovations in donor strategies and immunosuppression have enhanced success rates.
- Transplantation leads to substantial improvements in quality of life for pediatric patients.
Abstract:
Liver transplantation is an effective and widely accepted therapy for children with end-stage liver disease. Major indications include primary liver disease, resulting in hepatic insufficiency, or severe morbidity secondary to chronic non-progressive liver disease and metabolic diseases of the liver. Liver replacement should not be considered if there is an acceptable alternative therapy. Relative contraindications to transplantation include irreversible impairment of other organ systems, major systemic infection and diseases expected to recur after transplantation. Early referral for pre-transplant evaluation is important to confirm the proper diagnosis and determine priority for transplantation, to identify potential contraindications, and to assist in supportive care of the patient with chronic liver disease. Innovations such as reduced-sized liver grafts and most recently, living related liver transplantation have increased the donor supply of organs for small infants and significantly reduced pre-transplant mortality. In addition, living donor transplantation allows infants to benefit from transplantation before developing severe complications of end-stage liver disease and reduces the incidence of primary graft non-function and rejection. Immunosuppression following transplantation is maintained with methylprednisolone, azathioprine and cyclosporine. Acute rejection is treated with short bursts of high-dose corticosteroids and when necessary OKT3. With this approach, 90% of the episodes of rejection can be successfully controlled. Survival after transplantation has steadily improved and survival rates of 70%-90% are routine. Following transplantation, children experience rapid nutritional restoration, increased muscle strength, marked progress in gross motor development and improved general health.